Market Overview

Galmed Shares More Than Double As It Hits Bullseye With Fatty Liver Candidate

Galmed Shares More Than Double As It Hits Bullseye With Fatty Liver Candidate

Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) shares are on a tear after the Israeli pharma company reported positive trial results for its non-alcoholic stateohepatitis, or NASH, drug candidate.

The stock was ripping higher by 177.43 percent to $19.42 at the time of publication Tuesday. 

What Happened

Topline Phase 2b data released for Aramchol, evaluated in the global ARREST study in the treatment of NASH, showed a statistically significant reduction in liver fat. 

Aramchol is an oral, once-daily and liver-targeted SCD1 modulator.

The Israeli company said significantly more patients treated with Aramchol 600 mg vs. a placebo showed NASH resolution without worsening fibrosis in the 52-week biopsy. This is a regulatory approvable endpoint, Galmed said Tuesday. 

The pipeline candidate showed a favorable safety and tolerability profile, according to Galmed. 

Why It's Important

The results come as several companies — including Gilead Sciences, Inc. (NASDAQ: GILD), Allergan plc (NYSE: AGN), Bristol-Myers Squibb Co (NYSE: BMY) and Shire PLC (ADR) (NASDAQ: SHPG) — race to bring a NASH treatment to market. 

What's Next

The results of the two biopsy endpoints in the 600mg dose may become a primary endpoint for a Phase 3 trial to support Galmed's FDA marketing application, the company said. 

"We are excited with the ARREST results that will enable Galmed to meet with the regulators as soon as possible and discuss the pivotal study design," President and CEO Allen Baharaff said in a statement. 

Related Links:

Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate

The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs

Posted-In: AramcholBiotech News FDA Top Stories Movers Trading Ideas Best of Benzinga


Related Articles (AGN + BMY)

View Comments and Join the Discussion!

With inflation knocking on the Fed doors, two more rate hikes are still in play after June

Federal Reserve Lists Principal Economic Indicators